Beranda › Kanker Endometrium › Tennessee › Nashville
Uji klinis Kanker Endometrium di Nashville, TN
38 studi untuk Kanker Endometrium mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Menerima pesertaFase 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin · 17 mi jauhnya
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Menerima pesertaFase 2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Tennessee Oncology, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
- Research Site, Nashville
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Menerima pesertaFase 1
- Research Site, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Menerima pesertaFase 2
- Research Site, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institue, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Menerima pesertaFase 1/2
- Sarah Cannon Nashville, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Menerima pesertaFase 1/2
- GSK Investigational Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Menerima pesertaFase 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners - Nashville, Nashville
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Menerima pesertaFase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Menerima pesertaFase 1
- SCRI Oncology Partners, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Tennessee Oncology, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Uji klinis Kanker Endometrium di kota lain
- Houston, TX68 studi
- New York City, NY52 studi
- Boston, MA50 studi
- Arlington, VA39 studi
- Los Angeles, CA34 studi
- St. Louis, MO29 studi
- Philadelphia, PA28 studi
- San Antonio, TX27 studi
- Columbus, OH25 studi
- Oklahoma City, OK25 studi
- Chicago, IL25 studi
- Queens, NY25 studi
Studi lain di Nashville
- Kanker Paru Non-Sel Kecil97 studi
- Kanker Payudara81 studi
- Kanker Metastatik70 studi
- Kanker Kolorektal69 studi
- Kanker (semua jenis)65 studi
- Kanker Ovarium49 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Karsinoma Sel Skuamosa Kepala dan Leher39 studi
- Kanker Pankreas39 studi
- Melanoma33 studi
- Mieloma Multipel32 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.